EUCTR2004-000514-38-IE进行中（未招募）不适用
4T studyTreating to Target in Type 2 DiabetesA 36-month, Multi-centre, Open-label, Randomised, Parallel-group Trial Comparing the Safety, Efficacy and Durability of Adding a Basal Insulin versus a Twice Daily Insulin Mixture versus a Meal-time Rapid-Acting Insulin in Subjects with Type 2 Diabetes Inadequately Controlled on Therapy with Oral Agents, and Assessing the Requirement for more Complex Insulin Regimens to Achieve and Maintain Glycaemic Control, their Efficacy and Durability
ovo Nordisk Pharmaceuticals Ltd0 个研究点目标入组 700 人开始时间: 2004年6月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Informed consent obtained before any trial-related activities. Trial-related activities are any procedure that would not have been performed during normal management of the subject.
- •2) Subjects with type 2 diabetes of at least 12 months duration who are insulin naïve. Short term insulin treatment (7 days or less at any one time) is allowed.
- •3) OAD treatment for at least 4 months with metformin and a sulphonylurea. Subjects treated only with metformin or a sulphonylurea are also eligible if they have shown previous intolerance to sulphonylurea or metformin respectively.
- •4) The individual OAD dose(s) prior to inclusion must be either highest tolerated dose or at least half maximum recommended dose according to the local labelling for the OAD in question for the last 4 months before inclusion.
- •5) The OAD dose(s) should be unchanged for the last 4 weeks prior to inclusion.
- •6) Males and females, age =18 years.
- •7) Body mass index = 40.0 kg/m2.
- •8) 7.0 % = HbA1c = 10.0% at screening and based on analysis from the central laboratory.
- •9) Able and willing to use insulin injections for the entire trial period.
- •10) Able and willing to perform self-monitoring of plasma glucose.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Type 2 diabetic subjects currently receiving or having previously received insulin for more than 7 days at any one time.
- •2.Current or previous treatment with thiazolidinediones within the last 6 months.
- •3.Current or previous treatment with an alpha-glucosidase inhibitor, repaglinide or nateglinide within the past 30 days.
- •4.OAD treatment with three or more OADs within the last 6 months.
- •5.Diabetes other than Type 2 diabetes mellitus.
- •6.Known sight-threatening retinopathy as judged by the investigator.
- •7.Plasma creatinine =130 µmol/l.
- •8.Cardiac disease defined as:
- •Unstable angina pectoris within the last 6 months
- •Myocardial infarction (MI) within last 6 months
- •Congestive heart failure NYHA class III and IV
- •9Evidence of hepatic disease as determined by ALT values =2 x upper limit of normal.
- •10.Known hypoglycaemia unawareness or recurrent major hypoglycaemia as judged by the Investigator.
- •11.Anticipated change in dose of concomitant medication, which may interfere with glucose regulation, such as monoamine oxidase inhibitors (MAOI), beta-adrenergic agents, anabolic steroids or systemic glucocorticoids.
- •12.Uncontrolled hypertension measured as systolic blood pressure = 180 mmHg and / or diastolic pressure = 105 mmHg.
- •13.Known or suspected allergy to trial products or related products.
- •14.Any condition that the Investigator and / or the Sponsor feel would interfere with trial participation or the evaluation of results.
- •15.Mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation.
- •16.Pregnant or planning to become pregnant within the next 12 months, breast-feeding, or judged to be using inadequate contraceptive methods. Adequate contraceptive methods are sterilisation, intrauterine device (IUD), oral contraceptives or consistent use of barrier methods.
- •17.Receipt of any investigational trial drug within 3 months prior to participation in this trial.
- •18.Subjects previously screened for participation or having already participated in this trial.
研究者
相似试验
已完成
1 期
Treating To Target in Type 2 diabetesType 2 diabetesNutritional, Metabolic, EndocrineNon-insulin-dependent diabetes mellitusISRCTN51125379ovo Nordisk Limited (UK)700
已完成
1 期
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Insulin Icodec in Subjects With Type 2 DiabetesDiabetes Mellitus, Type 2NCT04582435Novo Nordisk A/S46
终止
1 期
Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00637338Pfizer42
已完成
1 期
A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study CompoundsHealthy VolunteersType 2 DiabetesNCT04676906Novo Nordisk A/S18
已完成
3 期
A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)Type 2 Diabetes MellitusNCT02791490Merck Sharp & Dohme LLC458